INSIGHTS ON CLINICAL TRIAL DESIGN

• Clinical Trial Evaluation And Referral Challenging For Physicians

  Physicians often encounter information gaps when evaluating clinical trials for patients. A recent survey indicates a fragmented, confusing trial information landscape that is difficult to navigate.

• Rare Disease R&D: Continued Growth Amid Challenges

  The market for rare disease treatments continues to grow but it is not without its challenges, including small patient populations and a lack of existing research.

• Living With An Invisible Disease: One Woman's Journey With CF

  Meet a clinical research participant who has spent her life navigating the challenges of cystic fibrosis, leading her to become an advocate, amplifying the voices of others facing similar struggles.

• Antibody-Drug Conjugates: 'Magic Bullets' Become Reality

  Cancer therapy has evolved from potent chemotherapy to targeted biological therapy, including antibody-drug conjugates (ADCs). Learn more about ADCs’ makeup, mechanisms, and the development landscape.

• Managing Drug And Data Requirements In Decentralized Clinical Trials

  9/15/2025

  Running a global decentralized clinical trial requires a deep understanding of the differences in FDA and EMA requirements for investigational products and patient data.

• How Some Patient Organizations Are Driving Drug Development

  9/17/2026

  Discover how patient-led registries are becoming a practical source of real-world evidence, drug repurposing insight, and smarter trial design.

• Phase I Clinical Trial Designs: Bayesian Logistic Regression Model (BLRM)

  9/25/2025

  The Bayesian Logistic Regression Model (BLRM) is redefining Phase I clinical trial design by bringing flexibility, precision, and patient-centered safety into early drug development.

• A Novel Digital Measure For Tracking Disease Progression In DMD

  2/6/2026
• Outgrowing Excel: Implementing RTSM In A Live Phase I Trial

  2/25/2026

  Learn how a clinical-stage oncology biotech successfully transitioned a live Phase I trial from manual spreadsheets to RTSM without disrupting site momentum or patient enrollment.